MEDLATEC SPOT-MAS Lung Cancer Screening

SPOT-MAS Lung is a blood-based screening test offered by MEDLATEC, designed to analyse biological signals associated with lung cancer.

Unlike multi-cancer screening tests, SPOT-MAS Lung focuses specifically on lung cancer. The test uses next-generation sequencing (NGS) and molecular analysis to examine cancer-associated signals in blood.

Key Benefits of SPOT-MAS Lung

• Blood-Based Screening

The test requires a blood sample without the need for tissue biopsy during the initial screening procedure.

• Focused Lung Cancer Screening

SPOT-MAS Lung specifically analyses biological signals associated with lung cancer, offering a targeted blood-based screening approach.

• Advanced Molecular Technology

The SPOT-MAS platform uses next-generation sequencing and computational analysis to evaluate cancer-associated molecular signals.

• Convenient Sample Collection

Blood collection generally takes only a few minutes, making the initial testing appointment convenient for international patients.

• Supports Further Medical Assessment

Screening results may help guide additional clinical investigation when appropriate. Further evaluation may include medical consultation, imaging, or other diagnostic procedures.

Who May Consider SPOT-MAS Lung?

Patients interested in lung cancer screening may discuss this test with a qualified healthcare professional.

Individual suitability depends on factors such as age, smoking history, family history, previous imaging results, and other lung cancer risk factors.

SPOT-MAS Lung should not be considered a replacement for guideline-recommended low-dose CT screening in eligible high-risk individuals.

Testing Process

1. Pre-Test Consultation: Review medical history, risk factors, and screening suitability.

2. Blood Sample Collection: A blood sample is collected for molecular analysis.

3. Laboratory Analysis: The sample undergoes molecular testing.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Follow-Up: Further medical evaluation may be recommended depending on the results.

Key Data

• Screening Focus: Lung Cancer

• Screening Method: Blood-Based Molecular Testing

• Technology: Next-Generation Sequencing (NGS)

• Sample Type: Blood

• Expected Result Time: Approximately 15 working days

• Location: Selected MEDLATEC facilities in Vietnam

Your Healthcare Journey in Vietnam with MediHub

MediHub is a strategic partner of MEDLATEC in supporting international patients travelling to Vietnam for healthcare services.

MediHub provides coordinated assistance throughout the patient's healthcare journey, from initial consultation and travel planning to medical appointments and post-visit follow-up.

Our support services may include:

• Healthcare package consultation and comparison

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during the stay

Plan Your Lung Cancer Screening in Vietnam

Considering lung cancer screening during your visit to Vietnam?

Contact MediHub to plan your healthcare journey. Our team can help coordinate suitable screening options, appointments with MEDLATEC, and travel arrangements according to your schedule.

Important Medical Information

SPOT-MAS Lung is a screening test, not a definitive diagnostic test. A positive result does not confirm lung cancer, and a negative result does not completely exclude it.

Blood-based screening should not replace established lung cancer screening recommendations or clinically indicated diagnostic imaging. Patients with symptoms or concerning findings should seek appropriate medical evaluation.